# Tigulixostat (IBI128) vs Febuxostat in Gout

> **NCT07414394** · PHASE3 · RECRUITING · sponsor: **Innovent Biologics Technology Limited (Shanghai R&D Center)** · enrollment: 600 (estimated)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Febuxostat
- **DRUG:** Tigulixostat

## Key facts

- **NCT ID:** NCT07414394
- **Lead sponsor:** Innovent Biologics Technology Limited (Shanghai R&D Center)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07414394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07414394, "Tigulixostat (IBI128) vs Febuxostat in Gout". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07414394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*